Oncotarget

Research Papers:

MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression

Wei Chen, Xin-Ke Xu, Jun-Liang Li, Kuan-Kei Kong, Hui Li, Cheng Chen, Jing He, Fangyu Wang, Ping Li, Xiao-Song Ge and Fang-Cheng Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:22783-22799. https://doi.org/10.18632/oncotarget.15199

Metrics: PDF 2208 views  |   HTML 1845 views  |   ?  


Abstract

Wei Chen1,2,3,*, Xin-Ke Xu1,*, Jun-Liang Li1,2,*, Kuan-Kei Kong1,2, Hui Li4, Cheng Chen1, Jing He1, Fangyu Wang1, Ping Li1, Xiao-Song Ge5, Fang-Cheng Li1,2

1Department of Neurosurgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, China

2Department of Neurosurgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China

3State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China

4Department of Respiratory, The First People's Hospital of Foshan, Sun Yat-Sen University, Guangdong Foshan 528000, China

5Department of Oncology, The Affiliated Hospital of Jiangnan University, Wuxi 214062, Jiangsu, China

*These authors contributed equally to this work

Correspondence to:

Fang-Cheng Li, email: sjwklfc@126.com

Xiao-Song Ge, email: Stanly8345@163.com

Keywords: MALAT1, temozolomide, chemoresistance, miR-203, thymidylate synthase

Received: December 06, 2016     Accepted: January 22, 2017     Published: February 08, 2017

ABSTRACT

Glioblastoma multiforme (GBM) is the most malignant brain tumor with limited therapeutic options. Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can’t be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis. By using the HiSeq sequencing and bioinformatics methods, we identified lncRNAs showing different expression levels in TMZ-resistant and non-resistant patients. RT-qPCR was then performed in tissues and serum samples, and lncRNA MALAT1 was finally identified to show considerable discriminating potential to identify responding patients from non-responding patients. Moreover, high serum MALAT1 expression was associated with poor chemoresponse and survival in GBM patients receiving TMZ treatment. Subsequently, the TMZ resistant cell lines were established, and the CCK8 assay showed that lncRNA MALAT1 knockdown significantly reversed TMZ resistance in GBM cells. The gain and loss-function experiments revealed that miR-203 was down-regulated by MALAT1 and this interaction has reciprocal effects. Besides, thymidylate synthase (TS) mRNA was identified as a direct target of miR-203. LncRNA MALAT1 inhibition re-sensitized TMZ resistant cells through up-regulating miR-203 and down-regulating TS expression. On the other hand, MALAT1 overexpression promoted resistance by suppressing miR-203 and promoting TS expression. In conclusion, our integrated approach demonstrates that enhanced expression of lncRNA MALAT1 confers a potent poor therapeutic efficacy and inhibition of MALAT1 levels could be a future direction to develop a novel therapeutic strategy to overcome TMZ resistance in GBM patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15199